MX340718B - Proceso y sistema para obtener neurotoxina botulinica. - Google Patents
Proceso y sistema para obtener neurotoxina botulinica.Info
- Publication number
- MX340718B MX340718B MX2014008854A MX2014008854A MX340718B MX 340718 B MX340718 B MX 340718B MX 2014008854 A MX2014008854 A MX 2014008854A MX 2014008854 A MX2014008854 A MX 2014008854A MX 340718 B MX340718 B MX 340718B
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum neurotoxin
- obtaining
- obtaining botulinum
- therapeutic
- research
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/145—Clostridium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un sistema cromatográfico sustancialmente libre de producto animal (APF) para obtener una neurotoxina botulínica biológicamente activa, caracterizada porque comprende: un primer aparato para cultivar la bacteria Clostridium botulinum, el primer aparato es capaz de contener un medio de cultivo sustancialmente APF; un segundo aparato para fermentar bacteria Clostridium botulinum, la cual ha sido cultivada en el primer aparato, el segundo aparato es capaz de contener un medio de fermentación sustancialmente APF; un tercer aparato para recolectar el medio de fermentación; un cuarto aparato para concentrar el medio de fermentación cosechado y diluir el medio de fermentación filtrado; un quinto aparato para llevar a cabo una primera purificación de la neurotoxina botulínica del medio cosechado en donde el quinto aparato comprende un medio de cromatografía de intercambio aniónico, por lo que se obtiene una primera neurotoxina botulínica purificada; y un sexto aparato para llevar a cabo una segundo purificación dela primera neurotoxina botulínica purificada en donde el sexto aparato comprende un medio de cromatografía de intercambio catiónico por lo que se obtiene una segunda neurotoxina botulínica purificada, en donde la neurotoxina boltulínica obtenida tiene una potencia de por lo menos aproximadamente 2.0 veces 107 unidades/mg de la neurotoxina botulínica, la neurotoxina botulínica obtenida comprende 1 ng o menos de 1 ng de ácido nucleico residual por cada mg de neurotoxina botulínica obtenida y el proceso se lleva a cabo en una semana o menos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/502,181 US8129139B2 (en) | 2009-07-13 | 2009-07-13 | Process for obtaining botulinum neurotoxin |
PCT/US2010/041745 WO2011008713A1 (en) | 2009-07-13 | 2010-07-12 | Process and system for obtaining botulinum neurotoxin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX340718B true MX340718B (es) | 2016-07-22 |
Family
ID=42537891
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008854A MX340718B (es) | 2009-07-13 | 2010-07-12 | Proceso y sistema para obtener neurotoxina botulinica. |
MX2012000615A MX2012000615A (es) | 2009-07-13 | 2010-07-12 | Proceso y sistema para obtener neurotoxina botulinica. |
MX2020009978A MX2020009978A (es) | 2009-07-13 | 2012-01-12 | Proceso y sistema para obtener neurotoxina botulinica. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000615A MX2012000615A (es) | 2009-07-13 | 2010-07-12 | Proceso y sistema para obtener neurotoxina botulinica. |
MX2020009978A MX2020009978A (es) | 2009-07-13 | 2012-01-12 | Proceso y sistema para obtener neurotoxina botulinica. |
Country Status (19)
Country | Link |
---|---|
US (19) | US8129139B2 (es) |
EP (5) | EP3640259A1 (es) |
JP (5) | JP5887268B2 (es) |
KR (5) | KR20180122039A (es) |
CN (2) | CN106117325B (es) |
BR (1) | BR112012000784A2 (es) |
CA (1) | CA2767760C (es) |
CY (2) | CY1119519T1 (es) |
DK (2) | DK2454275T3 (es) |
ES (2) | ES2643554T3 (es) |
HK (1) | HK1247629A1 (es) |
HU (2) | HUE047362T2 (es) |
IN (1) | IN2012DN00456A (es) |
MX (3) | MX340718B (es) |
PL (2) | PL3252070T3 (es) |
PT (2) | PT2454275T (es) |
RU (1) | RU2561459C2 (es) |
SI (2) | SI2454275T1 (es) |
WO (1) | WO2011008713A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
BRPI0508374A (pt) | 2005-03-03 | 2007-07-31 | Allergan Inc | meios para bactéria clostrìdio e processo para obtenção de uma toxina clostrìdica |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
PT2490986T (pt) | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
KR20110046178A (ko) * | 2009-10-28 | 2011-05-04 | 엘지전자 주식회사 | 이동 단말기 |
KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
US9605887B2 (en) | 2011-07-29 | 2017-03-28 | Hdt Expeditionary Systems, Inc. | Transportable packaged ice supply system for high temperature environments |
GB201113544D0 (en) * | 2011-08-05 | 2011-09-21 | Fujifilm Diosynth Biotechnologies Uk Ltd | Purification process |
WO2014197837A1 (en) * | 2013-06-06 | 2014-12-11 | University Of Florida Research Foundation, Inc. | Materials and methods for producing a biological toxin |
AU2014298922B2 (en) | 2013-07-30 | 2018-03-15 | Merz Pharma Gmbh & Co. Kgaa | Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof |
KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
KR20160068972A (ko) * | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
KR101729251B1 (ko) | 2015-04-28 | 2017-04-21 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
WO2017161345A1 (en) | 2016-03-18 | 2017-09-21 | Biomadison, Inc. | Improved cell based assay |
HRP20191966T4 (hr) | 2016-09-13 | 2022-09-16 | Allergan, Inc. | Stabilizirani neproteinski klostridijalni pripravci toksina |
KR102463881B1 (ko) * | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
RU2766147C2 (ru) * | 2017-03-22 | 2022-02-08 | Бонти, Инк. | Применение ботулинических нейротоксинов в лечении |
AU2018258591A1 (en) * | 2017-04-28 | 2019-11-07 | Bonti, Inc. | Botulinum neurotoxins production methods |
CA3068292A1 (en) * | 2017-06-26 | 2019-01-03 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
KR102140531B1 (ko) * | 2018-08-07 | 2020-08-04 | (주)휴온스 | Gly-Tβ4의 제조방법 |
JP7454507B2 (ja) | 2018-12-21 | 2024-03-22 | 一般財団法人阪大微生物病研究会 | ボツリヌス毒素の製造方法 |
KR102209159B1 (ko) * | 2019-03-29 | 2021-01-29 | (주)제테마 | 독소의 제조방법 |
KR102516203B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 제조방법 |
KR102485146B1 (ko) * | 2019-04-15 | 2023-01-06 | (주)제테마 | 보툴리눔 독소의 제조방법 |
US10851363B1 (en) * | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
KR102287437B1 (ko) * | 2019-08-14 | 2021-08-09 | 주식회사 프로톡스 | 보툴리눔 독소의 제조방법 |
TW202136286A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商葛德瑪控股公司 | 純化肉毒桿菌毒素的方法 |
TW202136518A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商葛德瑪控股公司 | 生產肉毒桿菌毒素的方法 |
KR20230009178A (ko) * | 2021-07-08 | 2023-01-17 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
KR102427362B1 (ko) * | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
KR20240015446A (ko) * | 2022-07-27 | 2024-02-05 | (주)이니바이오 | 감압건조장치 및 이를 이용한 감압건조방법 |
WO2024102345A1 (en) | 2022-11-07 | 2024-05-16 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401683A (en) * | 1981-07-06 | 1983-08-30 | Fmc Corporation | Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin |
CA2138020C (en) | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
TW257792B (es) * | 1992-10-01 | 1995-09-21 | Lilly Co Eli | |
JP3265577B2 (ja) | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白eの4型イソ型の測定法 |
US5314822A (en) | 1992-10-15 | 1994-05-24 | Merck & Co., Inc. | Method of clonal growth of Streptococcus pneumoniae |
GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
US5962637A (en) | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
WO1996005222A1 (en) | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
WO1996039167A1 (en) | 1995-06-06 | 1996-12-12 | Pearce L Bruce | Improved compositions and methods for chemodenervation using neurotoxins |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
EP1849860B1 (en) | 1997-05-28 | 2010-11-17 | Novartis Vaccines and Diagnostics S.r.l. | Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin |
JP4055248B2 (ja) | 1998-05-25 | 2008-03-05 | 味の素株式会社 | 精製ヒトアクチビン及びその製造方法 |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6558926B1 (en) | 1999-07-16 | 2003-05-06 | Massachusetts Institute Of Technology | Method for production of tetanus toxin using media substantially free of animal products |
WO2001036655A2 (en) | 1999-11-12 | 2001-05-25 | Eli Lilly And Company | Method for optimization of a medium for glycopeptide fermentation |
AU1486801A (en) | 1999-11-15 | 2001-05-30 | Curagen Corporation | Novel growth factor polypeptides and nucleic acids encoding same |
DE10004024A1 (de) | 2000-01-31 | 2001-08-02 | Guenther Bebenroth | Schaltungsanordnung zum Betreiben von Leuchtdioden |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
DE60125986T3 (de) | 2000-02-08 | 2011-07-28 | Allergan, Inc., 92612, Calif. | Pharmazeutische Zusammensetzungen mit Botulinum Toxin |
US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
CA2398799C (en) | 2000-02-10 | 2009-04-21 | Magna International Inc. | Vehicle tailgate with storage capacity |
JP2003009897A (ja) * | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
DE60226327T2 (de) * | 2001-08-14 | 2009-07-09 | Statens Serum Institut | Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin |
US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
US8022172B2 (en) | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
KR20030060150A (ko) | 2002-01-07 | 2003-07-16 | (주)메디톡스 | 클로스트리디움 보툴리눔 a형 독소를 정제하는 방법 |
RU2230325C2 (ru) * | 2002-08-15 | 2004-06-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ приготовления очищенного препарата ботулинического токсина типа а |
US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
DE602004005628T2 (de) * | 2003-07-02 | 2008-02-14 | Filtertek, Inc., Hebron | Halterung mit mehreren Brücken |
US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
US7160699B2 (en) * | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
US7452697B2 (en) * | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
US20070264373A1 (en) | 2004-01-26 | 2007-11-15 | Ian Carroll | Toxin Induced Sympathectomy |
ATE533853T1 (de) | 2004-02-24 | 2011-12-15 | Allergan Inc | Botulinumtoxin-screening-assays |
CA2578250C (en) | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060069562A1 (en) | 2004-09-10 | 2006-03-30 | Adams Marilyn J | Word categories |
US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
WO2006042149A2 (en) | 2004-10-06 | 2006-04-20 | Allergan, Inc. | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
US20070277577A1 (en) * | 2004-10-29 | 2007-12-06 | Allen Clyde G | Sheet metal brake and hinge mechanism therefor |
ES2395544T3 (es) | 2004-12-23 | 2013-02-13 | Novo Nordisk Health Care Ag | Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés |
BRPI0508374A (pt) | 2005-03-03 | 2007-07-31 | Allergan Inc | meios para bactéria clostrìdio e processo para obtenção de uma toxina clostrìdica |
DE602006014812D1 (de) | 2005-04-05 | 2010-07-22 | Allergan Inc | Lostridientoxinaktivität |
US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US7744904B1 (en) | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
BRPI0618753A2 (pt) | 2005-11-17 | 2011-09-13 | Revance Therapeutics Inc | composição para liberação transdérmica de toxina botulìnica e método de administração |
HUE046037T2 (hu) | 2008-03-14 | 2020-01-28 | Allergan Inc | Immun-alapú, A szerotípusú botulinum toxin aktivitás vizsgálati eljárások |
JP5826635B2 (ja) | 2009-03-13 | 2015-12-02 | アラーガン、インコーポレイテッドAllergan,Incorporated | 免疫系調節エンドペプチターゼ活性アッセイ |
US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
PT2490986T (pt) | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
NL2010545C2 (en) | 2013-03-28 | 2014-09-30 | Ihc Holland Ie Bv | Skidding system for an offshore installation or vessel. |
US9889608B2 (en) | 2014-11-10 | 2018-02-13 | International Business Machines Corporation | Matching the scale of independent objects or intelligently scaling objects when 3D printing |
-
2009
- 2009-07-13 US US12/502,181 patent/US8129139B2/en active Active
-
2010
- 2010-07-12 EP EP19200775.5A patent/EP3640259A1/en not_active Withdrawn
- 2010-07-12 EP EP17180720.9A patent/EP3252070B1/en active Active
- 2010-07-12 HU HUE17180720A patent/HUE047362T2/hu unknown
- 2010-07-12 CN CN201610487340.0A patent/CN106117325B/zh active Active
- 2010-07-12 MX MX2014008854A patent/MX340718B/es unknown
- 2010-07-12 PL PL17180720T patent/PL3252070T3/pl unknown
- 2010-07-12 ES ES10733117.5T patent/ES2643554T3/es active Active
- 2010-07-12 SI SI201031560T patent/SI2454275T1/sl unknown
- 2010-07-12 PL PL10733117T patent/PL2454275T3/pl unknown
- 2010-07-12 CA CA2767760A patent/CA2767760C/en active Active
- 2010-07-12 KR KR1020187031605A patent/KR20180122039A/ko active Application Filing
- 2010-07-12 WO PCT/US2010/041745 patent/WO2011008713A1/en active Application Filing
- 2010-07-12 ES ES17180720T patent/ES2770031T3/es active Active
- 2010-07-12 KR KR1020177003936A patent/KR101916139B1/ko active IP Right Grant
- 2010-07-12 KR KR1020197027795A patent/KR102344985B1/ko active IP Right Grant
- 2010-07-12 DK DK10733117.5T patent/DK2454275T3/en active
- 2010-07-12 CN CN201080038953.7A patent/CN102482332B/zh active Active
- 2010-07-12 IN IN456DEN2012 patent/IN2012DN00456A/en unknown
- 2010-07-12 RU RU2012104778/10A patent/RU2561459C2/ru active
- 2010-07-12 KR KR1020127003603A patent/KR101784532B1/ko active IP Right Grant
- 2010-07-12 DK DK17180720.9T patent/DK3252070T3/da active
- 2010-07-12 KR KR1020157018698A patent/KR101667174B1/ko active IP Right Grant
- 2010-07-12 JP JP2012520707A patent/JP5887268B2/ja active Active
- 2010-07-12 MX MX2012000615A patent/MX2012000615A/es active IP Right Grant
- 2010-07-12 HU HUE10733117A patent/HUE033888T2/en unknown
- 2010-07-12 SI SI201031966T patent/SI3252070T1/sl unknown
- 2010-07-12 BR BR112012000784-0A patent/BR112012000784A2/pt not_active Application Discontinuation
- 2010-07-12 PT PT107331175T patent/PT2454275T/pt unknown
- 2010-07-12 EP EP23194794.6A patent/EP4299070A3/en active Pending
- 2010-07-12 PT PT171807209T patent/PT3252070T/pt unknown
- 2010-07-12 EP EP10733117.5A patent/EP2454275B1/en active Active
- 2010-07-12 EP EP22185200.7A patent/EP4141024A1/en not_active Withdrawn
-
2012
- 2012-01-05 US US13/344,420 patent/US8357541B2/en active Active
- 2012-01-05 US US13/344,399 patent/US8927229B2/en active Active
- 2012-01-12 MX MX2020009978A patent/MX2020009978A/es unknown
- 2012-02-28 US US13/407,662 patent/US8932827B2/en active Active
- 2012-05-10 US US13/468,889 patent/US8324349B2/en active Active
-
2014
- 2014-12-05 US US14/561,402 patent/US9206409B2/en active Active
-
2015
- 2015-10-30 JP JP2015214835A patent/JP6356651B2/ja active Active
- 2015-12-07 US US14/961,327 patent/US9719076B2/en active Active
-
2016
- 2016-11-10 JP JP2016219708A patent/JP6704329B2/ja active Active
-
2017
- 2017-07-31 US US15/664,456 patent/US10465178B2/en active Active
- 2017-10-11 CY CY20171101055T patent/CY1119519T1/el unknown
-
2018
- 2018-06-01 HK HK18107202.9A patent/HK1247629A1/zh unknown
-
2019
- 2019-11-04 US US16/673,444 patent/US11124786B2/en active Active
- 2019-12-31 CY CY20191101367T patent/CY1122567T1/el unknown
-
2020
- 2020-01-09 JP JP2020001854A patent/JP2020078306A/ja not_active Withdrawn
-
2021
- 2021-06-07 US US17/340,720 patent/US11203748B2/en active Active
- 2021-09-01 JP JP2021142559A patent/JP2021193103A/ja active Pending
- 2021-10-19 US US17/505,537 patent/US11326155B2/en active Active
-
2022
- 2022-01-19 US US17/579,208 patent/US11525130B2/en active Active
- 2022-03-15 US US17/694,962 patent/US20220204958A1/en not_active Abandoned
- 2022-03-15 US US17/694,932 patent/US11518986B2/en active Active
- 2022-04-29 US US17/732,951 patent/US20220251532A1/en not_active Abandoned
- 2022-06-08 US US17/835,503 patent/US11530400B2/en active Active
- 2022-09-27 US US17/953,789 patent/US20230021648A1/en not_active Abandoned
- 2022-09-27 US US17/953,882 patent/US20230029327A1/en active Pending
- 2022-12-19 US US18/084,505 patent/US20230123158A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009978A (es) | Proceso y sistema para obtener neurotoxina botulinica. | |
MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
MX2019006519A (es) | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. | |
MX2019010735A (es) | Sistemas y metodos para la produccion dirigida de una proteina terapeutica dentro de una celula objetivo. | |
SA515360928B1 (ar) | متقارنات جسم مضاد جديدة واستخداماتها | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
ECSP099804A (es) | Proteinas de fusion del receptor para productos finales de glicacion avanzada | |
UA109278C2 (uk) | Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань | |
BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
EP2575856A4 (en) | INNOVATIVE DISCOVERY OF THERAPEUTIC COMPOSITIONS, DIAGNOSTICS AND ANTIBODIES RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-ARNT SYNTHETASES | |
MX2012003770A (es) | Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia. | |
EP2568996A4 (en) | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF PHENYLALANYL BETA-TRNA SYNTHETASES | |
MX2020010991A (es) | Composicion para la estimulacion ovarica controlada. | |
WO2011047103A3 (en) | Cell reprogramming with applications for epigenetic and non-epigenetic base induced pluripotent stem cell derivation | |
MX368142B (es) | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. | |
EP2596122A4 (en) | MODULATORS OF SIRT5 AND TESTS FOR SCREENING | |
DK2027266T3 (da) | Multimer til immunstilmulering | |
PH12014502243A1 (en) | Novel bacillus subtilis | |
GEP201706709B (en) | Process and apparatus for metering plasticized formulation | |
PH12017500047A1 (en) | Dual cistronic bacterial expression system | |
GB2525562A (en) | Devices and methods for purification of biological cells | |
EP3432714A4 (en) | TREATMENT OF CANCER BASED ON THE ADMINISTRATION OF OLIGONUCLEOTIDES THROUGH LACUNAR JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (HMSC) | |
MX2018010196A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. | |
MX350713B (es) | Variantes de subtilisina y polinucleotidos que las codifican. | |
AR068038A1 (es) | Polipeptidos de la hormona de crecimiento modificada |